Takeuchi Yasuhiro
Toranomon Hospital Endocrine Center, Japan.
Clin Calcium. 2012 Jun;22(6):897-903.
Remarkable progress in development of anti-fracture drugs has been achieved. Now we have anti-resorptive drugs, bisphosphonates and selective estrogen receptor modulators (SERMs) , bone anabolic one, teriparatide, and active vitamin D(3) analogues, alfacalcidol and eldecalcitol. Accumulating evidence shows their anti-fracture efficacy and safety profiles. We should learn fundamental evidence of those medicines as prescribing them to patients with osteoporosis.
抗骨折药物的研发已取得显著进展。现在我们有抗吸收药物,如双膦酸盐和选择性雌激素受体调节剂(SERM),骨合成代谢药物特立帕肽,以及活性维生素D(3)类似物阿法骨化醇和依地骨化醇。越来越多的证据表明了它们的抗骨折疗效和安全性。在给骨质疏松症患者开这些药物时,我们应该了解这些药物的基本证据。